Recent News

• 11.04.2026 - Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
• 11.03.2026 - Cytokinetics to Participate in November Investor Conferences
• 11.02.2026 - Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
• 10.21.2026 - Cytokinetics to Announce Third Quarter Results on November 4, 2026
• 10.19.2026 - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.19.2026 - Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
• 10.12.2026 - Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
• 10.02.2026 - Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
• 09.30.2026 - Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
• 09.17.2026 - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - 8-K Current report
• 11.04.2026 - EX-99.1 EX-99.1
• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.20.2026 - 4 Statement of changes in beneficial ownership of securities